Hemogenyx Pharmaceuticals plc (LSE: HEMO), formerly named Silver Falcon plc (“Silver Falcon”), a business formed for the purpose of acquiring another business or asset, reports its Final Results for the year ended 31 December 2017. The business of the Company is now the development of therapies for the treatment of blood diseases.
All financial amounts are stated in GBP British pounds unless otherwise indicated.
Key highlights
- Successful acquisition of Hemogenyx Pharmaceuticals for £8m in shares in October 2017
- Change of name to Hemogenyx Pharmaceuticals Plc
- £2m raised in a Placing and Subscription
- LakePharma, Inc. appointed as service provider for development of, CDX bi-specific antibodies
- University of Oxford collaboration aims to accelerate development of blood cancer treatments
- Overall work is progressing successfully towards the goal of submitting an IND application to the FDA
Post-period end highlights
- First data results show CDX antibodies can attack and eliminate Acute Myelogenous Leukemia in vitro
- Patent application filed relating to new type of humanised mouse (with chimeric mouse-human blood system)
- Appointment of Sir Marc Feldmann, pioneer of anti-TNF therapy, as Executive Chairman
- Appointment of cancer research expert Dr Michael Shepard to Scientific Advisory Board
- Collaboration with major US biotechnology firm worth up to US$250,000
Dr. Vladislav Sandler, CEO of Hemogenyx, said:
“2017 was a significant year for Hemogenyx as we successfully listed the business on the London Stock Exchange and raised the financing necessary to further develop novel therapies with the potential to transform the lives of bone marrow transplant patients. We remain on track in the development of both of our products according the timescale we outlined to investors in October. We continue to successfully develop our Hu-PHEC cell therapy product and we are on course to have our CDX antibodies product in readiness for the start of Phase 1 trials as planned.”
| Hemogenyx Pharmaceuticals Limited | www.hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder Dr Robin Campbell, Chairman |
Via Walbrook PR |
| Optiva Securities Ltd | Tel: +44 (0)20 3137 1902 |
| Christian Dennis | |
| Shard Capital Partners LLP | Tel: +44 (0)20 7186 9950 |
| Damon Heath, Erik Woolgar | |
| Peterhouse Corporate Finance Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey | |
| Walbrook PR (UK Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com |
| Paul McManus | Mob: +44 (0)7980 541 893 |
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company’s leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx’s two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.